nimustine has been researched along with Acute Lymphoid Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumabe, T; Nagamatsu, K; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M | 1 |
| Ogawa, M; Ueda, T; Yamauchi, T | 1 |
2 other study(ies) available for nimustine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Convection; Cranial Irradiation; Drug Delivery Systems; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Nimustine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stereotaxic Techniques | 2011 |
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadmium Chloride; Carmustine; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Mismatch Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Guanine; Humans; Hydroxylamines; Nimustine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide | 2008 |